SGLT2 INHIBITORS
Clinical trials for SGLT2 INHIBITORS explained in plain language.
Never miss a new study
Get alerted when new SGLT2 INHIBITORS trials appear
Sign up with your email to follow new studies for SGLT2 INHIBITORS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Diabetes drug could help stop liver damage in hepatitis b patients
Disease control OngoingThis study tests whether empagliflozin, a diabetes drug, can prevent liver scarring (fibrosis) from getting worse in people with chronic hepatitis B. About 106 participants with moderate to severe liver scarring will take either empagliflozin or a placebo daily for three years. T…
Matched conditions: SGLT2 INHIBITORS
Phase: PHASE4 • Sponsor: The University of Hong Kong • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Diabetes drug class may change how the bladder behaves
Knowledge-focused OngoingThis study looks at how SGLT-2 inhibitors, a common class of diabetes drugs, affect lower urinary tract symptoms such as frequent urination, urgency, and nighttime trips to the bathroom. Researchers will follow adults with type 2 diabetes who are starting an SGLT-2 inhibitor for …
Matched conditions: SGLT2 INHIBITORS
Sponsor: Marmara University • Aim: Knowledge-focused
Last updated Jul 23, 2026 00:00 UTC